ABSTRACT Drug receptor kinetics is as a key component in drug discovery, development, and efficacy; however, determining kinetic parameters has historically required direct radiolabeling or competition with a labeled tracer. Here we present a simple approach to determining the kinetics of competitive antagonists of G protein-coupled receptors by exploiting the phenomenon of hemi-equilibrium, the state of partial re-equilibration of agonist, antagonist, and receptor in some functional assays. Using functional [Ca 21 ] i -flux and extracellular kinases 1 and 2 phosphorylation assays that have short incubation times and therefore are prone to hemi-equilibrium "behaviors," we investigated a wide range of structurally and physicochemically distinct muscarinic acetylcholine receptor antagonists. Using a combined operational and hemi-equilibrium model of antagonism to both simulate and analyze data, we derived estimates of association and dissociation rates for the test set of antagonists, identifying both rapidly dissociating (4-DAMP, himbacine) and slowly dissociating (tiotropium, glycopyrrolate) ligands. The results demonstrate the importance of assay incubation time and the degree of receptor reserve in applying the analytical model. There was an excellent correlation between estimates of antagonist pK B , k on , and k off from functional assays and those determined by competition kinetics using whole-cell [
Introduction
In recent years, the importance of the kinetics of a drug binding to its receptor has become readily accepted as a key parameter in the drug discovery process. Recent literature on kinetic analysis of preclinical candidates has aided in understanding the mechanism of action of these compounds and their contribution to therapeutic efficacy. For example, methyl]-2-({(2R)-1- [4-(4-{[3-(hexahydro-1H-azepin-1-yl) propyl]oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1(2H)-phthalazinone (GSK1004723) was identified as a potent histamine H 1 R and H 3 R antagonist for the treatment of allergic rhinitis, with a kinetically driven long duration of action (Slack et al., 2011) . Tiotropium and glycopyrronium bromide (NVA237), which have both yielded positive phase 3 results in the treatment of chronic obstructive pulmonary disease (Jones, 2015) , have greater kinetic selectivity for the M 3 muscarinic acetylcholine receptor (mAChR) compared with other mAChR family members, in line with the documented large therapeutic index of these drugs (Sykes et al., 2012) . More recently, antagonists of the orexin-2 receptor for the treatment of insomnia could be differentiated based on their kinetic parameters, with almorexant being identified as a pseudoirreversible antagonist (Mould et al., 2014) .
Typically, kinetic parameters of compounds are rarely optimized during early stage drug discovery, as this often requires labeling the compounds with a suitable radioisotope or the addition of a fluorescent moiety. Although these approaches can provide direct and precise data, both are extremely costly, technically challenging, and normally reserved for a select subset of compounds. One alternative approach, amenable to early stage drug discovery, is the method of Motulsky and Mahan (1984) . In this method, the binding of a kinetically well defined radioligand is monitored in the presence or absence of a competitor ligand. Changes to the kinetic rates of the radioligand can be analyzed and the rates of the competitor ligand determined (Dowling and Charlton, 2006) . Obviously, the major limiting factor to this method is the availability of a robust, high-affinity radioligand.
Hemi-equilibrium is a phenomenon in functional assays whereby a reversible, competitive antagonist produces a depression in the maximal agonist response owing to insufficient agonist-antagonist-receptor re-equilibration time between the addition of agonist (to initiate a response) and the measurement of the response. Such effects are typically seen in transient assay readouts, such as calcium assays (Charlton and Vauquelin, 2010) . A competitive antagonist can display a range of behaviors, from fully surmountable to fully insurmountable antagonism, subject to both the kinetics of ligand binding and assay reequilibration time (Gaddum, 1957) .
Analysis of these "equilibrium artifacts" has previously revealed that the depression of the maximal agonist response is directly related to the dissociation rate of the competing antagonist (Christopoulos et al., 1999; Mathiesen et al., 2006) . Accordingly, we hypothesized that this effect could be exploited to profile the binding kinetics of a range of mAChR antagonists in functional assays with different incubation times; however, functional assays are also subject to the added phenomenon of "receptor reserve," which can mask the effects of insurmountable antagonists (Kenakin et al., 2006) . For example, (S)-N-methyl-N (4-[4-acetylamino-4-phenylpiperidino]-2-(3,4-dichlorophenyl) butyl)benzamide (SR 48968), a nonpeptide tachykinin NK 2 receptor antagonist has been labeled as either a surmountable or insurmountable antagonist in functional experiments, depending on the different tissues and different species used (Patacchini et al., 2000) .
To determine the utility of functional assays to provide quantitative estimates of ligand binding kinetics, a system is required that is amenable to profiling both in functional assays while also using a more traditional approach by competitive radioligand binding kinetics (Dowling and Charlton, 2006) . To validate our method, we used Flp-In-CHO cells stably expressing the M 1 mAChR, a physiologically relevant buffer, whole-cell competition kinetics, and [Ca 21 ] i -flux and ERK1/2 phosphorylation functional assays. The M 1 mAChR was chosen because it is a prototypical family A G protein-coupled receptor (GPCR) that has been widely characterized in multiple binding and functional assays and has a wide range of comprehensively studied, structurally distinct, competitive antagonists available as pharmacologic tools (Christopoulos et al., 1999; Jakubik et al., 2006) . Radioligand binding kinetics were analyzed according to the method of Motulsky and Mahan (1984) , whereas functional data were analyzed using a combined operational/ hemi-equilibrium model of competitive antagonism (Kenakin, 2009 ). Herein we demonstrate the feasibility of using functional assays to estimate kinetic rates of unlabeled antagonists without the necessity of a suitable radioligand. This method promises significant impact on early stage drug discovery, enabling receptor kinetics to be incorporated into the traditional structure activity relationship process.
Materials and Methods
Cell Line Generation and Culture Conditions of Flp-In-CHO-hM 1 mAChR. CHO-M 1 mAChR cell lines were generated as previously described by Avlani et al. (2007) . For binding studies 7000 FlpIn-CHO-hM 1 mAChR cells per well (100 ml final volume per well) were seeded in F-12 GlutaMax containing 10% fetal bovine serum (FBS) into 96-well ISOPLATE TC plates the day before experimentation and allowed to grow overnight at 37°C and 5% CO 2 . For all functional experiments 30,000 cells per well (100 ml final volume per well) were seeded in F-12 GlutaMax containing 10% FBS into clear 96-well plates the day before experimentation and incubated for 8 hours at 37°C and 5% CO 2 prior serum starving the cells with 100 ml of F-12 GlutaMax, overnight.
Common Procedures Applicable to All Radioligand Binding Experiments. Radioligand binding experiments were performed on Flp-In-CHO cells stably expressing the hM 1 mAChR. The following day after plating, cells were washed with phosphate-buffered saline (100 ml) and resuspended in binding buffer (110 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgSO 4 , 25 mM glucose, 20 mM HEPES, and 58 mM sucrose; pH 7.4 with NaOH). As a result of the rapid association of [ 3 H]N-methylscopolamine (NMS) at 37°C, all experiments were performed at 22°C. Assay mixtures, in a total volume of 200 ml with a 1:10 dilution of drug, were incubated at 22°C. Assays were terminated by buffer removal after by rapid washing, twice, with ice-cold 0.9% NaCl (100 ml). Plates were allowed to dry inverted for 30 minutes; OptiPhase Supermix scintillation cocktail (100 ml) was added, plates were sealed (TopSeal), and radioactivity was measured in a MicroBeta2 LumiJET microplate counter. Saturation binding experiments were performed in the absence or presence of atropine (100 mM Determination of Antagonist Affinity Constants (pK I ) and Kinetic Parameters (k on and k off ) on Whole Cells. To determine the kinetic parameters of unlabeled antagonists a competition kinetic binding assay was used (Dowling and Charlton, 2006 Cheng and Prusoff (1973) . Experiments were initiated by the coaddition of [ 3 H]NMS (0.4 nM) and unlabeled competitor to plated cells. Then 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP), atropine, himbacine, ipratropium, N-methyl scopolamine (NMS), and pirenzepine were tested at 1, 3, and 10Â K I , glycopyrrolate, and quinuclidinyl benzylate at 10, 30; 100Â K I and tiotropium were tested at 30, 100, and 300Â K I , as determined in the equilibrium binding assay. Assays were terminated as described here.
[Ca 21 ] i -Flux Assay. On the day of the experiment, the cells were washed with 100 ml of phosphate-buffered saline. The cells were then incubated with Ca 21 assay buffer (110 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgSO 4 , 25 mM glucose, 20 mM HEPES, and 58 mM sucrose, 0.5% (w/v) bovine serum albumin (BSA), and 4 mM Probenecid, pH 7.4) containing 2 mM Fluo-4-AM for 1 hour under humidified conditions at 37°C. Each assay plate was then loaded into a FLEXstation (Molecular Devices Inc., Sunnyvale, CA) with its stock compound plate. The FLEXstation measured fluorescence over a 75-second time period using 485-nm excitation and 538-nm emission wavelengths and performed the addition of drugs (1:10 dilution) at the 15-second time point. For all interaction studies, mAChR antagonists were added 30 minutes before agonist stimulation. For each interaction, the peak of maximum florescence induced by the addition of either methacholine (MCh) or acetylcholine (ACh), between 15 and 75 seconds was chosen, and corrected to the baseline (fluorescence from 0 to 14 seconds) and then normalized to 1 mM ACh-mediated response.
ERK1/2 Phosphorylation Assay. Initial ERK1/2 phosphorylation time course experiments were performed to determine the time at which ERK1/2 phosphorylation was maximal after stimulation by MCh or ACh. For subsequent agonist-stimulated concentration response experiments, cells were incubated at 37°C with each agonist for the 5 minutes required to achieve peak response. For interaction experiments, mAChR antagonists were incubated for 30 minutes before agonist stimulation. In all experiments, 10% FBS was used as a positive control. The reaction was terminated by removal of drugs and lysis of cells with 80 ml of SureFire lysis buffer (TGR Biosciences, Thebarton, SA, Australia). The lysates were agitated for 1 to 2 minutes, and 5 ml was transferred into 384-Optiplate (PerkinElmer Life and Analytical Sciences) prior addition of a mixture of Surefire activation buffer, Reaction buffer and Acceptor/Donor beads (10:60: 0.3:0.3) in a total volume of 13.5 ml. Plates were incubated in the dark at 37°C for 60 minutes, then 22°C for 10 minutes, before the fluorescence signal was measured using an Envision plate reader (PerkinElmer Life and Analytical Sciences, Melbourne, VIC, Australia) using standard AlphaScreen settings.
Determination of cLogD pH7.4 Values. These values were obtained using ChemAxon MarvinSketch version 14.11.10.0 (Budapest, Hungary) using a weighted LogP method, with this method being the arithmetic mean of methods of Viswanadhan et al., (1989) , Klopman et al. (1994) , and PHYSPROP database (SRI, Inc., Syracuse, NY).
Compounds and Reagents. The mAChR antagonists were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Radioligand was purchased from PerkinElmer. Cell culture and molecular biology reagents were supplied by Life Technologies (Melbourne, VIC, Australia).
Data Analysis. Because the amount of radioactivity varied slightly for each experiment (,5%), data are shown graphically as the mean 6 S.D. from a single fit to grouped data of individual experiments, and values reported in the text and tables are mean 6 S.D. for the indicated number of experiments. All experiments were analyzed by either linear or nonlinear regression using Prism 6.0f (GraphPad Software Inc., San Diego, CA) as described in the following sections.
Saturation Binding. Saturation binding isotherms were globally fitted to nonspecific and total binding data, and individual estimates for total receptor number (B max ) and radioligand dissociation constant (K D ) were calculated as in eq. 1:
where Y is the radioligand binding, B max is the total receptor density, [A] is the concentration of radioligand, K A is the equilibrium dissociation constant of the radioligand, and NS is the fraction of nonspecific radioligand binding: Competition Binding. Competition displacement binding data were fitted to sigmoidal three-parameter logistic eq. 2:
where Y is the percent of bound radioligand. Top denotes maximal asymptotic binding, and bottom denotes the minimal asymptotic binding. IC 50 values obtained from the inhibition curves were converted to pK I values using the method of Cheng and Prusoff (1973) . Association Binding.
[ 3 H]NMS association data were globally fitted (eq. 3). k on and k off were shared across the data sets so that a single value for each was derived from the whole family of curves:
where k obs 5 [radioligand] Â k on 1 k off ; Y 5 specific binding (counts per minute); Y max 5 maximal specific binding and X 5 time.
Competition Binding Kinetics. Association and dissociation rates for unlabeled antagonists were calculated by using the equations (eq. 4) described previously by Motulsky and Mahan (1984) :
where X 5 time (minutes); Y 5 specific binding (counts per minute); ] i -flux and ERK1/2 phosphorylation assays were fitted to the following form of an operational model of agonism (eq. 5) (Black and Leff, 1983 ):
where E m is the maximal possible response of the system (not the agonist), Basal is the basal level of response in the absence of agonist, K A denotes the functional equilibrium dissociation constant of the agonist (A), t is an index of the coupling efficiency (efficacy) of the agonist and is defined as R T /K E , where R T is the total concentration (B max ) of receptors and K E is the concentration of agonist-receptor complex that yields half the maximum system response (E m ). To define the E m and t of ACh and MCh in each assay, the K A for each agonist was constrained to equal the K I value derived from radioligand binding assays (see Results) in the nonlinear regression procedure. Schild Analysis. To estimate antagonist affinity values, agonist concentration-response data in the presence of increasing concentrations of antagonist were fitted to the following form of Schild regression analysis (eq. 6) (Arunlakshana and Schild, 1959; Motulsky and Christopoulos, 2004 ):
where E is response, E max and basal are the top and bottom asymptotes of the curve, respectively, log[A] is the logarithm of the agonist concentration, pEC 50 is the negative logarithm of the agonist concentration that gives a response halfway between E max and basal, s represents the Schild slope for the antagonist, and pA 2 represents the negative logarithm of the molar concentration of antagonist necessary to double the concentration of agonist needed to elicit the original submaximal response obtained in the absence of antagonist. Operational/Hemi-Equilibrium Model for Competitive Antagonism. If compounds showed a depression of the agonist E max , data were fitted according to a combined operational/hemiequilibrium model for competitive antagonism under nonequilibrium conditions (Kenakin, 2009; Mould et al., 2014) , and estimates of antagonist affinity values, pK B , and their dissociation constant from the receptor, k off , were determined as in eq. 7:
where: ), t is the assay incubation time (minutes), t is
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the operational efficacy of the selected agonist (comprising cell-and agonist-dependent properties), and E m is the maximal system response. All parameters were shared across all data sets except t, which was fixed to the assay incubation time, 0.2 minute in [Ca 21 ] i -flux assay, and 5 minutes in ERK1/2 phosphorylation assay, and K A , which was constrained to equal the K I value derived from radioligand binding assays in the nonlinear regression procedure.
Linear Correlations and Statistical Analysis. Correlations between datasets were determined by calculating the Pearson correlation coefficient (r 2 ) and associated two-tailed P value, with a P , 0.05 deemed statistically significant.
Simulations of the Effects of Hemi-Equilibrium. Data simulations to determine the effects of antagonist dissociation rate on agonist curve translocation were generated using the combined operational/ hemi-equilibrium model of antagonism (eq. 7) with the following values or ranges: K A 5 0.1 mM, K B 5 0.1 mM, Log t 5 1-100, k off 5 0.00120.1, E m 5 1, time 5 1-100 minutes, and [B] 5 0.1, 0.3, 1.0, 3.0, or 10.0 mM. 6 sites cell per well, and the equilibrium dissociation constant (pK D ) was determined to be 9.46 6 0.02 (Table 1) .
Results
To enable a robust method to be used to evaluate the kinetic parameters of unlabeled mAChR antagonists (Fig. 1) curves were converted to pK I values using the method of Cheng and Prusoff (1973) . Data for the mAChR antagonists are summarized in Table 2 .
Competition Binding Kinetics Using Whole Cells. To calculate the kinetic rates of unlabeled mAChR, antagonist association and dissociation rates of [ 3 H]NMS in the presence and absence of competitor were determined, and these values were used to calculate k on (k 3 ) and k off (k 4 ) by globally fitting the individual experimental data sets to eq. 4, as described in Materials and Methods. Grouped data curves to atropine and tiotropium are shown in Fig. 3 ; graphs for the remaining ligands are shown in Supplemental Fig. 1 . Data for all ligands are summarized in Table 2 . Each ligand was tested over a range of concentrations to demonstrate competitive and reversible binding (Sykes et al., 2012) . Higher concentrations and increased sampling time of the slow dissociating ligands were used to allow equilibrium to be reached. The difference in profiles is consistent with that observed for slowly dissociating ligands, where an initial overshoot occurs before equilibrium is reached (Dowling and Charlton, 2006; Mould et al., 2014) .
There was an excellent correlation between kinetically derived pK D and the equilibrium competition binding pK I values ( Fig. 4A; Significant correlation was found between equilibrium dissociation constants and both k on and k off values, as shown in Fig. 4B (r 2 5 0.65, P 5 0.0088) and 4c (r 2 5 0.50, P 5 0.03), respectively. These data suggest that both parameters drive affinity, an observation previously made for b 2 -adrenoceptor ligands (Sykes et al., 2012) ; however, there are examples in the literature where it has been shown that affinity can be driven by k off alone, for example, the D 2 receptor (Kapur and Seeman, 2001) , or k on alone, for example, the OX 2 receptor (Mould et al., 2014) . Compounds in the current test set appear to fall into two clear clusters where compounds with weak affinity, for example himbacine and pirenzepine, display slow-on and fast-off kinetics; compounds with high affinity, for example, atropine and tiotropium, display rapid k on and slow k off kinetics (Fig. 4) .
Effect of cLogD pH7.4 on the Rate Constants. In an attempt to understand why these ligands fell into two groups based on their kinetic rates, the effect of lipophilicity (cLogD pH7.4 values, Table 2 ) was investigated. Significant correlation (r 2 5 0.72, P 5 0.007) was found between Log k on and cLogD pH7.4 (Supplemental Fig. 2A) ; however, no correlation was observed between the Log k off and cLogD pH7.4 (Supplemental Fig. 2B ).
Simulations of Hemi-Equilibrium and the Effects of Stimulus-Response Coupling. Our hypothesis is that the dissociation rate of unlabeled ligands can also be quantitatively estimated using the hemi-equilibrium model for competitive antagonism under nonequilibrium conditions (Kenakin, 2009 ); however, this method relies heavily on a significant and saturable depression of the maximal response of the control agonist in the presence of increasing concentrations of antagonist. We postulated that the effects of agonist-antagonistreceptor equilibration time and the combined efficacy of the agonist and the total receptor density, t, as measured by the operational model of agonism (Black and Leff, 1983) could play a large part in determining the optimal conditions to observe hemi-equilibrium.
To guide our experimental design, simulations of agonist concentration-response curves in the presence of increasing concentrations of antagonist were constructed using a combined 3 H]NMS for various time periods. Association data were fitted to a global fitting model using Prism 6.0f to simultaneously to calculate k on and k off , and are summarized in Table 1 . Grouped data are shown 6 S.D. (n = 3). 
Kinetics of mAChR Ligands in Binding and Functional Assays
operational/hemi-equilibrium model of competitive antagonism (Kenakin, 2009; Mould et al., 2014) . In an assay of modest receptor reserve (t 5 10; typical of many functional screening assays) and with a fixed incubation time of 10 minutes, an antagonist with a receptor half-life of t 1/2 % 7 minutes (k off 5 0.1 minute
21
) is predicted to display a surmountable profile (Fig.  5A ). An antagonist with a receptor t 1/2 % 70 minutes (k off 5 0.01 minute
) is predicted to yield a significant but saturable depression in the maximal response, characteristic of hemiequilibrium. A compound with an extended residence time (t 1/2 % 700 minutes; k off 5 0.001 minute
) would be predicted to display an essentially insurmountable antagonist profile (Fig.  5C ). Simulations of antagonist profiles under different assay incubation times reveal a similar pattern; an antagonist with a receptor t 1/2 % 70 minutes can appear surmountable or insurmountable or display a hemi-equilibrium profile, depending on the length of agonist-antagonist-receptor reequilibration time (Fig. 5, D-F) . The degree of receptor reserve present in the functional assay is also predicted to have a marked effect on the observed antagonist profile; varying the value of t for the agonist from 1 to 100 yields a similar variety of curve-shift profiles (Fig. 5, G-I) . Thus, a number of assay parameters contribute to the observed antagonist profile, making it important to identify the correct conditions to yield, and hence analyze, hemi-equilibrium effects. This is reinforced by the observation that it is not possible to recover the parameters used to simulate data by analysis with the model for antagonists that fully collapse the agonist concentration-response curve (Fig. 5J) . Therefore, finding optimal experimental conditions is a prerequisite to using the operational/hemi-equilibrium model of antagonism for kinetic parameter determinations.
To experimentally demonstrate these effects, concentrationresponse curves to ACh and MCh were constructed and Log t ]NMS with 1, 3, and 10Â K I for atropine, or 30, 100, and 300Â K I for tiotropium. Plates were incubated for the indicated time points at room temperature. Nonspecific bind levels were determined in the presence of 10 mM atropine. Data were globally fitted to the equations as described in Materials and Methods to calculate k on , k off , and kinetically-derived K D values for the unlabeled agonists and are summarized in Table 2 . Grouped data are shown 6 S.D. (n = 3). ] i -flux assay, Log t values of 2.84 6 0.06 and 1.94 6 0.06 were determined for ACh and MCh, respectively (Fig. 6A) . Lower efficacies were seen in ERK1/2 phosphorylation assays, with Log t values of 2.19 6 0.11 and 1.35 6 0.10 (Fig. 6B) for ACh and MCh, respectively. In both the [Ca 21 ] i -flux and ERK1/2 phosphorylation assays, ACh had high efficacy and was therefore deemed a full agonist. The potencies of ACh were left-shifted compared with its affinity (pK I 5 4.55; Table 2 ), suggesting a high receptor reserve within these systems for this agonist. MCh, however, had significantly lower efficacy than ACh, even though it has the same maximal response as ACh and slightly higher affinity (pK I 5 4.80; Table 2 ). As a result, MCh may be a more suitable agonist to detect the kinetic effects in assays with higher receptor reserve.
Experimental Data of Hemi-Equilibrium and the Effects of Stimulus-Response Coupling. To demonstrate experimentally the effects of equilibration time and receptor reserve, concentration-response curves to ACh and MCh were constructed in the presence and absence of atropine and tiotropium as prototypical fast and slow dissociating antagonists, respectively Atropine produced a concentrationdependent rightward shift in the ACh concentration-response curve in both the [Ca 21 ] i -flux and ERK1/2 phosphorylation assays with only a small depression in the E max (Fig. 7, A and B) . Conversely, when MCh was used, atropine gave a concentrationdependent rightward shift in the MCh concentration-response curve in both assays with a markedly greater depression in the E max (Fig. 7, C and D) , in accordance with the lower efficacy of this ligand. These data were analyzed using the combined operational/hemi-equilibrium model of antagonism, as described in Materials and Methods, to estimate pK B and k off values.
Analysis of the data sets using ACh did not converge sufficiently to provide reproducible estimates of receptor t 1/2 values, whereas the data for MCh provided robust parameter estimates (14 6 2 and 27 6 1 minutes for [Ca 21 ] i -flux and ERK1/2 phosphorylation, respectively). The slowly dissociating antagonist, tiotropium, abolished the MCh response in the [Ca 21 ] i -flux assay, precluding meaningful analysis using the model (Fig. 7E ). In the ERK1/2 phosphorylation assay, however, it produced a saturable depression of the maximal MCh response, yielding an estimated t 1/2 5 223 6 85 minutes (Fig. 7F ).
An excellent agreement was obtained for the k off values derived from radioligand binding and functional assays for both atropine (0.05 6 0.01 min 21 in [Ca 21 ] i -flux and 0.03 6 0.01 in ERK1/2 phosphorylation versus 0.07 6 0.05 in binding) and tiotropium (0.003 6 0.002 min 21 in ERK1/2 phosphorylation versus 0.006 6 0.001 in binding). The pK B values for atropine from both assays were also in excellent agreement with those obtained in the competition binding kinetics (9.44 6 0.08 in [Ca 21 ] i -flux and 9.23 6 0.21 in ERK1/2 phosphorylation versus 9.18 6 0.06 in binding). A similarly excellent agreement was obtained for tiotropium (10.25 6 0.26 in ERK1/2 phosphorylation versus 10.05 6 0.16 in binding).
Given the agreement across datasets for these exemplar compounds and the improved data resolution using MCh as the agonist probe, we generated kinetic parameter estimates for our set of competitive antagonists. These data are summarized in Table 3 and represented graphically in Supplemental Fig. 3 . Some compounds clearly demonstrate surmountable antagonism, for example, 4-DAMP and himbacine, indicative of rapid dissociation. Because of their apparent rapid re-equilibration in the time frame of the assay, the t 1/2 for these compounds could not be determined; however, a reasonable estimate would be that the half-lives for such compounds would be equal to or less than the assay incubation time.
Unsurprisingly, there was a very robust correlation between the binding kinetics derived pK D and the functional hemi-equilibrium derived pK B (r 2 5 0.97, P , 0.0001), which is shown in Fig. 8A . More interestingly, an excellent correlation was also obtained between the radioligand binding k off and the functional hemi-equilibrium k off (r 2 5 0.94, P 5 0.0004), shown in Fig. 8C . Furthermore, a similarly excellent correlation was also obtained between the radioligand binding k on and the functional hemi-equilibrium k on (calculated post hoc by k off /K B values; r 2 5 0.90, P 5 0.0012), shown in Fig. 8B .
Discussion
Herein we provide a framework for assessing kinetic rate constants for competitive antagonists for a GPCR using functional assays. Previously, it has been shown that the dissociation rate of a competitive antagonist is proportional to its propensity to depress the maximal response to an agonist in a functional assay as a result of incomplete agonistantagonist-receptor re-equilibration (Christopoulos et al., 1999) . This phenomenon was originally termed hemiequilibrium (Paton and Rang, 1965; Vauquelin et al., 2002) . Taking advantage of this effect, we show that application of an operational/hemi-equilibrium model of antagonism to functional data yields kinetic rate constants that are in excellent agreement with those derived from radioligand binding assays. This approach does not require a fluorescent or radiolabeled probe but rather a functional assay in which the agonist-antagonist-receptor incubation time is in the range of 1-100 times the receptor half-life for the antagonist. In practice, most commonly used GPCR functional assays fall into this category, highlighting its generic utility.
Using the muscarinic M 1 receptor as a test system, we generated kinetic rate constant estimates for a range of antagonists by [ 3 H]NMS binding. Analysis revealed a wide range of affinity and rate constant estimates. Both k on and k off values significantly correlate with antagonists' equilibrium dissociation constants (Fig. 4) , indicating that for this set of structurally diverse compounds, both association and dissociation rates drive equilibrium affinity. Interestingly, compounds of weak affinity (e.g., himbacine and pirenzepine) tended to display slow association but rapid dissociation kinetics. Conversely, compounds that had higher affinity (e.g., NMS and tiotropium) displayed faster association but slow dissociation kinetics. To design an optimal functional assay under hemiequilibrium conditions, we performed simulations of functional data using the operational/hemi-equilibrium model. These predicted the importance of antagonist k off values, assay incubation time, and degree of stimulus-response coupling in achieving hemi-equilibrium. It is obvious that shorter assay incubation times and/or more slowly dissociating antagonists would give rise to non-equilibrium effects; simulations indicate that there is a range of these parameters that yield a saturable depression in the E max amenable to analysis (Fig. 5) . Outside this range, there is either sufficient agonist-antagonist-receptor re-equilibration (yielding a surmountable profile) or no reequilibration (resulting in an insurmountable profile; Fig. 5 ). Therefore, these simulations reveal a potential "sweet spot" of k off values that can be identified for a given assay incubation time, where the product of incubation time, and k off is in the approximate range 0.01 to 1.
In functional assays, "receptor reserve" is dependent on both the level of receptor expression ([R T ]) and the efficiency of the agonist-receptor complex to elicit a response (K E ; Ariens et al., ] i -flux assay or 5 minutes for the ERK1/2 phosphorylation assay, with fluorescence being measured over a 75-second time period using 485-nm excitation and 538-nm emission wavelengths, or termination of the assay using the SureFire lysis buffer. Cell lysates were analyzed using an AlphaScreen ERK1/2 phosphorylation assay kit. Data were globally fitted to the equations as described in Materials and Methods to calculate pK B and k off values for the unlabeled agonists and are summarized in Table 3 . Grouped data are shown 6 S.D. (n = 3 or 4).
1960
; Adham et al., 1993; Umland et al., 2001) . The operational parameter t encompasses both terms (R T /K E ). Data simulations revealed that the degree of receptor reserve has as much influence as the incubation time and antagonist k off ; very slow-off compounds could appear surmountable when t values are high (Fig. 5 ). In keeping with this observation, the analytical model performance improved when we used the partial agonist, MCh, in place of the full agonist, ACh, in our Flp-In-CHO-hM 1 functional assays. Subsequent profiling of the antagonists in the functional assays yielded estimates of dissociation rate constants that were in excellent agreement with those derived from [ 3 H]NMS binding studies (r 2 5 0.94, P 5 0.0004; Fig. 8 ). It was noteworthy that compounds displaying very rapid dissociation in the radioligand binding (e.g., 4-DAMP and himbacine) appeared fully surmountable, even in the [Ca 21 ] i -flux assay, precluding analysis using the hemi-equilibrium model. Accordingly it would be predicted that their t 1/2 values would be equal to, or less than, the assay incubation time (#15 seconds). The revelation that common functional assays can be used to determine antagonist kinetics gives rise to several insights and opportunities. For example, it has long been apparent that agonist pharmacology is influenced by receptor reserve. Herein we demonstrate that differences in receptor reserve markedly affect antagonist pharmacology and the ability to resolve rate constants. Only when the partial agonist, MCh (rather than ACh) was used were robust parameter estimates obtained for antagonist binding kinetics. Nonetheless, with appropriate assay design (which may include optimization of incubation time, the level of receptor expression or efficacy of probe agonist), simple functional assays can be adapted to routinely determine antagonist kinetics for any GPCR with the same level of confidence as would be provided by more traditional radioligand binding approaches. This potentially adds value to drug discovery programs that may seek particular kinetic properties (Sykes et al., 2012; Christopher et al., 2015) . Kinetic properties have also been shown to underlie discrepancies between in vitro and in vivo data for compounds (Ramsey et al., 2011; Mould et al., 2014; Sykes et al., 2014a) .
Similarly, this approach may also be used to differentiate tool antagonists on the basis of their kinetics. Many of the recent advances in X-ray structure determination of GPCRs have arisen by generating receptor cocomplexes with high affinity and slowly dissociating antagonists (Rasmussen et al., 2011; Haga et al., 2012; Manglik et al., 2012) ; our approach offers a generic method for simply assessing candidate tool compounds based on their kinetic parameters. A final consideration is that receptor kinetics may contribute to pathwayspecific affinity states and biased agonism at GPCRs. A number of "antagonists" have been shown to display hitherto unappreciated agonistic effects, for example, propranolol and carvedilol at the b 2 -adrenoceptor (Baker et al., 2003a; Wisler et al., 2007) and atropine at the muscarinic M 3 receptor (Stewart et al., 2010) . Furthermore, there is no a priori reason why antagonists may not display differential affinities dependent on the pathway/effector system being monitored (Kenakin, 2014) ; propranolol has a 5-fold higher affinity to inhibit adrenaline-stimulated cAMP accumulation compared with CRE-SPAP transcription at the b 2 -adrenoceptor (Baker et al., 2003b) , and even larger differences have been observed for a 1B -adrenoceptor antagonists (Yoshiki et al., 2014) . The reason for multiple antagonist affinity states remains largely unknown, but it is possible that the residence time of ligands may contribute to differential signal pathway activation/ inhibition.
Both the radioligand binding and functional assays reveal a range of association and dissociation rates. The slower association of some ligands to the M 1 receptor may be due to their physicochemical properties; Sykes et al. (2014b) have shown that lipophilicity and membrane compartmentalization of a ligand can have profound effects on binding kinetics. For this test set of compounds, the association rate was significantly correlated with the compounds' distributioncoefficient (cLogD 7.4 ; r 2 5 0.72, P 5 0.007). Interestingly, there was no correlation of cLogD 7.4 with dissociation rate (r 2 5 0.18), suggesting that once bound, egress of a molecule from the M 1 mACh receptor is not significantly influenced by its lipophilicity. The apparent inverse relationship between association rate and antagonist lipophilicity of the ligand is in contrast to the profile observed for the b 2 -adrenoceptor (Sykes et al., 2014b) and indicates that the initial interaction with the M 1 mAChR may not favor lipophilic compounds. Compounds with high lipophilicity may first partition in to the cell membrane before accessing the receptor-binding site, consequently slowing their association. Conversely, compounds with low lipophilicity and weak membrane affinity may interact directly with the extracellular vestibule of the receptor, similar to the radioligand, [ 3 H]NMS. From molecular dynamics simulations, Dror et al. (2011) described, for both the b 1 -and b 2 -adrenergic receptors, that the b-blocker alprenolol bound initially to a region in the extracellular vestibule, 15 Å away from the orthosteric site, before traversing to the binding pocket. Currently, our ability to measure ligand rate constants is based on competition with a ligand bound in the orthosteric-binding pocket. Consequently, we measure a combination of the complete binding process, and perhaps the physicochemical properties of a ligand play a greater part in overcoming the energy barriers, as described by Dror et al. (2011) . Investigation into these additional binding sites by use of fluorescent ligands, mutagenesis, or inhibition of the orthosteric pocket by irreversible or slowly dissociating ligands may help elucidate the importance of these interactions and identify a ligands complete residency time at the receptor.
In conclusion, we have provided a framework for the rapid and simple assessment of competitive antagonist binding kinetics at GPCRs using widely available functional assays. With judicious experimental design, application of an analytical model of hemi-equilibrium provided estimates of muscarinic M 1 receptor antagonist rate constants that were in excellent agreement with those determined by classic radioligand binding approaches. This generic method offers an approach to profile receptor kinetics without the need for labeled probes, opening up the possibility to determine kinetic parameters for GPCR antagonists as a structure activity relationship parameter in drug discovery, to discriminate tool compounds or to probe the pharmacology underlying observedbiased agonism or antagonism. 
